{"id":112764,"date":"2021-04-27T17:10:00","date_gmt":"2021-04-27T17:10:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=28657052865705"},"modified":"2021-04-27T17:10:00","modified_gmt":"2021-04-27T17:10:00","slug":"non-small-cell-lung-cancer-pipeline-insights-100-key-pharma-players-and-100-therapies-to-look-out-for-in-the-non-small-cell-lung-cancer-pipeline-landscape","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/04\/27\/non-small-cell-lung-cancer-pipeline-insights-100-key-pharma-players-and-100-therapies-to-look-out-for-in-the-non-small-cell-lung-cancer-pipeline-landscape\/","title":{"rendered":"Non-Small Cell Lung Cancer Pipeline Insights: 100+ Key Pharma Players and 100+ Therapies to Look Out for in the Non-Small Cell Lung Cancer Pipeline Landscape"},"content":{"rendered":"

\"\"<\/p>\n

Non-Small Cell Lung Cancer Pipeline Insights: 100+ Key Pharma Players and 100+ Therapies to Look Out for in the Non-Small Cell Lung Cancer Pipeline Landscape<\/strong><\/p>\n

Key players, such as <\/span>AstraZeneca, AbbVie, Roche, Merk, Novartis, Pfizer, Takeda Pharmaceuticals, Johnson & Johnson, Sanofi, Xcovery, Jiangsu Alphamab Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group<\/strong>, etc., are involved in developing drugs for Non-Small Cell Lung Cancer (NSCLC).<\/span><\/p>\n

DelveInsight\u2019s \u201c<\/span>Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight Report 2021<\/strong><\/a><\/span>,\u201d lays out comprehensive insights about 10+ companies and pipeline drugs in the Non-Small-Cell Lung cancer competitive landscape.\u00a0<\/span><\/p>\n

The NSCLC Pipeline insights report offers a 360\u00b0 view of the therapeutics landscape by:<\/span><\/p>\n

    \n
  1. Development stage<\/span><\/li>\n
  2. Product type<\/span><\/li>\n
  3. Route of administration<\/span><\/li>\n
  4. Molecule type<\/span><\/li>\n
  5. Mechanism Of Action\u00a0<\/span><\/li>\n<\/ol>\n

    The<\/span> Non-Small Cell Lung Cancer pipeline report<\/strong><\/a> lays down the business opportunities, threats, future collaborations, strong competitors, and growth strategies.\u00a0<\/span><\/p>\n

    Key highlights from our report:<\/strong><\/p>\n

      \n
    1. The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer (NSCLC) R&D.\u00a0<\/span><\/li>\n
    2. The therapies under development focus on novel approaches to treat\/improve Non-Small-Cell Lung cancer (NSCLC).<\/span><\/li>\n
    3. Incyte Corporation, in collaboration with Zai Lab Limited, is investigating their drug candidate, INCMGA00012 (MGA012), which is a proprietary humanized monoclonal Antibody<\/span><\/li>\n
    4. Janssen, a Johnson and Johnson Company, is currently investigating their lead product JNJ-61186372 (JNJ-6372) in Advanced NSCLC patients.<\/span><\/li>\n
    5. Apart from these therapies, there are some other potential emerging therapies are also in development for NSCLC, which are in phase I and I\/II and have the potential to impact the dynamics of the NSCLC therapeutics market such as LAG3 (i.e., Eftilagimod alpha (Immutep), BI754111 (Boehringer Ingelheim), LAG525 (Novartis)).<\/span><\/li>\n<\/ol>\n

      Request for Sample @Non-Small Cell Lung Cancer Pipeline Insights and Outlook<\/a><\/strong><\/p>\n

      Non-Small Cell Lung Cancer is a form of cancer in which malignant (cancer) cells develop in lung tissues.<\/span><\/p>\n

      NSCLC is a common form of lung cancer that accounts for around 85% of all lung cancers. However, NSCLC metastasis to other organs slower than SCLC, and microscopically, SCLC is composed of much smaller cells. Adenocarcinomas, squamous cell carcinomas, giant cell carcinomas, and adenosquamous carcinomas are the most common forms of NSCLC. Adenosquamous carcinomas and sarcomatoid carcinomas are less common.<\/span><\/p>\n

      Non-Small Cell Lung Cancer pipeline analysis: Drug Profile<\/strong><\/a><\/span><\/p>\n

      The NSCLC Pipeline appears quite vast and rich with over 100 pharmaceutical companies in dynamically advancing the NSCLC pipeline forward developing novel therapeutic agents in different clinical stages. The NSCLC pipeline report proffers a comprehensive analysis of key companies including Novartis Pharmaceuticals, Jiangsu Alphamab Biopharmaceuticals, AbbVie, Janssen Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Cstone Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Merck, Merck\/Pfizer, Amgen, Mirati Therapeutics\/Bristol-Myers Squibb, Beigene, Incyte Corporation, Xcovery, Daiichi Sankyo, Inc., Shanghai Henlius Biotech, Qilu Pharmaceutical and several others with their pipeline therapeutic agents.\u00a0<\/span><\/p>\n

      1.\u00a0Nazartinib\/EGF816 by Novartis Pharmaceuticals<\/strong><\/p>\n

      In patients with advanced EGFR-mutant NSCLC, it is a third-generation EGFR TKI that selectively targets activating (L858R, ex19del) and resistance (T790M) mutants while sparing wild-type EGFR. EGF816 covalently binds to mutant forms of EGFR, including the T790M EGFR mutant, and inhibits their activity after oral administration, preventing EGFR-mediated signalling.<\/span><\/p>\n

      2. Telisotuzumab Vedotin by AbbVie<\/strong><\/p>\n

      It is an antibody-drug conjugate (ADC) targeting c-Met that is being investigated to treat NSCLC. Upon intravenous administration, the monoclonal antibody moiety of Telisotuzumab Vedotin targets and binds to c-Met expressed on tumour cells.\u00a0<\/span><\/p>\n

      3. JNJ-61186372\/JNJ-6372 by Janssen Pharmaceuticals<\/strong><\/p>\n

      Janssen, a Johnson and Johnson Company, is currently investigating their lead product JNJ-61186372 (JNJ-6372) in Advanced NSCLC patients. It is a novel Human Bispecific EGFR and c-Met Antibody that the company believes can benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.<\/span><\/p>\n

      4. Canakinumab (ACZ885) by Novartis Pharmaceuticals<\/strong><\/p>\n

      It is an injectable human monoclonal antibody intended to bind to human interleukin-1 beta (IL-1 beta). Its mode of action is based on the neutralization of 1\u03b2 signalling, resulting in suppressing inflammation in patients with disorders of autoimmune origin.<\/span><\/p>\n

      Dive deeper to know more @ Non-Small Cell Lung Cancer therapeutics and drugs pipeline<\/a><\/strong><\/p>\n

      Non-Small Cell Lung Cancer (NSCLC) Key Pharma Players Involved:<\/strong><\/p>\n

        \n
      1. \u00a0<\/span>Novartis Pharmaceuticals<\/li>\n
      2. Jiangsu Alphamab Biopharmaceuticals<\/span><\/li>\n
      3. AbbVie<\/span><\/li>\n
      4. Janssen Pharmaceuticals<\/span><\/li>\n
      5. Chia Tai Tianqing Pharmaceutical Group<\/span><\/li>\n
      6. Cstone Pharmaceuticals<\/span><\/li>\n
      7. Novartis Pharmaceuticals<\/span><\/li>\n
      8. Takeda Pharmaceuticals<\/span><\/li>\n
      9. Sanofi<\/span><\/li>\n
      10. Merck<\/span><\/li>\n
      11. Merck\/Pfizer<\/span><\/li>\n
      12. Amgen<\/span><\/li>\n
      13. Mirati Therapeutics\/Bristol-Myers Squibb\/Beigene<\/span><\/li>\n
      14. Incyte Corporation<\/span><\/li>\n
      15. Xcovery<\/span><\/li>\n<\/ol>\n

        Non-Small Cell Lung Cancer (NSCLC) Therapies Involved:<\/strong><\/p>\n

          \n
        1. Nazartinib\/EGF816<\/span><\/li>\n
        2. KN046<\/span><\/li>\n
        3. Telisotuzumab Vedotin<\/span><\/li>\n
        4. TQB2450<\/span><\/li>\n
        5. Sugemalimab\/CS1001<\/span><\/li>\n
        6. Canakinumab (ACZ885)<\/span><\/li>\n
        7. Veliparib<\/span><\/li>\n
        8. TAK-788<\/span><\/li>\n
        9. SAR408701<\/span><\/li>\n
        10. TEPMETKO (tepotinib)<\/span><\/li>\n
        11. Avelumab<\/span><\/li>\n
        12. AMG 510<\/span><\/li>\n
        13. Sitravatinib (MGCD516)<\/span><\/li>\n
        14. INCMGA00012\/MGA012<\/span><\/li>\n
        15. Ensartinib\/X-396<\/span><\/li>\n<\/ol>\n

          Non-Small Cell Lung Cancer pipeline therapeutics assessment:<\/strong>\u00a0<\/span><\/p>\n